Next-Gen Hemophilia Treatments Offer Hope for Joint Health, but Accessibility Challenges Remain

The future of hemophilia care lies not only in technological advancements but also in the pursuit of health equity, ensuring that all patients have access to effective, affordable treatments.

Image Credit: RFBSIP-stock.adobe.com

Despite significant advances in hemophilia treatment, joint damage and chronic pain are persistent challenges for those living with the disorder, especially in low-resource settings where cutting-edge therapies are often out of reach. New research published in Expert Review of Hematology highlights the urgent need to protect joint health in individuals with hemophilia through innovative therapies, early diagnostic tools, and a focus on health equity.

This review explores recent innovations aimed at preserving joint health and addressing health disparities in hemophilia care, especially for underserved populations and those in low-resource settings. Hemophilia, an inherited bleeding disorder, presents significant challenges for affected individuals, primarily through spontaneous or injury-induced bleeding episodes. These bleedings, especially in joints, often lead to chronic joint damage and arthropathy, severely limiting movement, causing pain, and reducing overall quality of life.

Progress in Joint Health and Hemophilia Treatment

In recent years, hemophilia treatment has evolved with the development of extended half-life (EHL) products that improve replacement therapies for deficient clotting factors VIII (FVIII) and IX (FIX). While these therapies have shown promise in reducing bleeding frequency and severity, therapies like emicizumab-kxwh (Hemlibra) can come at a high cost to patients.² Regardless, the review underscored that joint bleeding and resulting damage continue to present significant barriers to health, especially for those with severe forms of the disease and limited access to treatment options.¹

Emerging therapies, including FVIII and FIX mimetics, aim to reduce bleeding by promoting thrombin generation, even in patients with inhibitors—antibodies that interfere with clotting factors and make treatment more challenging. These innovative therapies are mainly available in high-income countries, leaving many patients in low- and middle-income countries with limited treatment options. Additionally, the authors highlighted that bleeding remains a risk with trauma and injuries, underscoring the need for more preventative and early detection tools.

Challenges in Addressing Health Disparities in Hemophilia Care

More than 80% of the global hemophilia population lacks access to current advanced treatments, specifically concentrated in low- and middle-income countries. Health disparities in hemophilia care are exacerbated by limited access to diagnosis, treatment, and specialized care, resulting in prolonged disability and reduced life expectancy. Therefore, research priorities emphasize equity in health care access, particularly in under-resourced regions like Africa, Eastern Europe, Southeast Asia, and Latin America.

Furthermore, hemophilia has historically been viewed as a male-dominated disorder, given its X-linked genetic nature. However, women and individuals with the potential to menstruate can also experience hemophilia-related bleeding and joint issues.³ They often face underdiagnosis and minimal support, highlighting the need for gender equity in hemophilia care.

Innovative Approaches to Diagnose and Monitor Joint Health

Advances in diagnostics and clinical assessment tools have become essential for early detection and management of hemophilia-related joint damage.¹ The integration of point-of-care technologies and routine joint ultrasounds enables clinicians to assess joint health, monitor inflammation, and identify early signs of synovitis—joint membrane inflammation that can lead to arthropathy if untreated. These tools are especially valuable in managing hemophilia in resource-limited settings, as they allow for more proactive care and monitoring.

"Although desirable, the availability of advanced and adequate medical management may only be a realistic expectation in well-resourced countries," the authors wrote. "For most of the world’s hemophilia population, including countries like India, joint bleeding and hemophilic arthropathy remains a significant problem due to the lack of adequate treatment, although cost-effective alternatives are being examined."

Precision Medicine and Future Therapeutics

Precision diagnostics, including genetic testing and advanced coagulation tests, play a crucial role in improving hemophilia outcomes. Research into new therapies aims to create treatments that manage hemophilia, minimize long-term joint damage, and support an active lifestyle for individuals living with the disorder. Additionally, bioinformatics is being used to design the next generation of therapeutic interventions, offering hope for more individualized and effective treatment options.

In the coming decade, advances in gene therapy and non-factor therapies are expected to further reduce disparities in outcomes and bring this patient population closer to achieving a quality of life comparable to their unaffected peers. Ongoing research into curative treatments, such as gene editing, could potentially offer long-lasting solutions for individuals with hemophilia, particularly as these therapies become more accessible globally.

References

1. Mancuso ME, McLaughlin P, Forsyth AL, Valentino LA. Joint health and pain in the changing hemophilia treatment landscape. Expert Rev Hematol. 2024;17(8):431-444. doi:10.1080/17474086.2024.2378936

2. Grossi G. HSSP pharmacists demonstrate substantial cost avoidance in specialty medication use. AJMC^®. October 28, 2024. Accessed November 5, 2024. https://www.ajmc.com/view/hssp-pharmacists-demonstrate-substantial-cost-avoidance-in-specialty-medication-use

3. Grossi G. Breaking barriers in bleeding disorders: experts call for more data on women. Am J Account Care. 2024;12(1):38-40. doi.org/10.37765/ajac.2024.89525